Literature DB >> 16521119

Investigation of the phase diagrams of chiral praziquantel.

Yue Liu1, Xin Wang, Jing-Kang Wang, Chi Bun Ching.   

Abstract

In the present work, thermal properties of praziquantel, including melting point phase diagram and solubility, were determined for the purpose of exploration on an integrated enantioseparation process of chromatography and crystallization. The solubility of racemic praziquantel in methanol and 2-propanol was measured in the temperature range between 0 and 40 degrees C. In agreement with previous conclusions, the resulting phase diagram reveals the racemic compound behavior of praziquantel arising from the existence of eutectics. A ternary phase diagram of praziquantel enantiomers and the methanol system was also determined. Based on the information provided by the ternary solubility phase diagram, an optimized integrated enantioseparation process was suggested. Pure praziquantel crystals were recovered, and the crystal structure was solved by X-ray crystallography. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16521119     DOI: 10.1002/chir.20251

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  3 in total

1.  Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug Praziquantel.

Authors:  Ana Borrego-Sánchez; Alfonso Hernández-Laguna; C Ignacio Sainz-Díaz
Journal:  J Mol Model       Date:  2017-03-08       Impact factor: 1.810

2.  New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.

Authors:  Stefano Guglielmo; Daniela Cortese; Francesca Vottero; Barbara Rolando; Valerie P Kommer; David L Williams; Roberta Fruttero; Alberto Gasco
Journal:  Eur J Med Chem       Date:  2014-07-03       Impact factor: 6.514

3.  Mechanochemical Formation of Racemic Praziquantel Hemihydrate with Improved Biopharmaceutical Properties.

Authors:  Debora Zanolla; Dritan Hasa; Mihails Arhangelskis; Gabriela Schneider-Rauber; Michele R Chierotti; Jennifer Keiser; Dario Voinovich; William Jones; Beatrice Perissutti
Journal:  Pharmaceutics       Date:  2020-03-23       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.